{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T15:48:26Z","timestamp":1758124106614,"version":"3.30.0"},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":2495,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2008,11]]},"abstract":"<jats:sec>\n            <jats:title>Abstract<\/jats:title>\n            <jats:p>\n                                 <jats:bold>The Siemens VERSANT\u00ae transcription-mediated amplification (TMA) assay is extremely sensitive for the detection of hepatitis C virus (HCV) RNA in serum. Eleven of 180 subjects in the Hepatitis C Antiviral Long-term Treatment against Cirrhosis (HALT-C) Trial who achieved polymerase chain reaction (PCR)-defined sustained virological response (SVR) at week 72 also had TMA-positive results from the same blood draw; six were positive on repeat testing. We report the follow-up on these 11 patients, and the reproducibility of TMA test results from PCR-negative samples in relationship to antiviral treatment outcome. Peginterferon and ribavirin treatment was initiated in 1145 prior interferon nonresponders with advanced hepatic fibrosis. Treatment was continued for 48 weeks if patients had undetectable HCV RNA by PCR at treatment week 20. Frozen serum samples from weeks 12, 20, 24, 48, and 72 were subsequently tested by TMA. Nine of the 11 patients returned for testing (median, 30 months after the week 72 visit), and all had undetectable HCV RNA by TMA and PCR. Among 759 PCR-negative samples obtained during treatment that were tested twice by TMA, 17% overall exhibited consistently positive results, and 21% exhibited inconsistently positive results. SVR was more likely if TMA was consistently negative than if consistently or inconsistently positive. With continued treatment, patients with inconsistently positive TMA results were more likely to become TMA-negative than TMA-positive (<\/jats:bold>\n                                 <jats:bold>\n                                    P\n                                 <\/jats:bold>\n                                 <jats:bold>&lt; 0.0001).<\/jats:bold>\n                                 <jats:bold>\n                                    Conclusion:\n                                 <\/jats:bold>\n                                 <jats:bold>In PCR-negative samples, positive TMA results may indicate the presence of low levels of HCV RNA. However, because patients with positive TMA results may achieve SVR, management decisions during therapy should not be based on a single positive TMA test result. (Hepatology 2008.)<\/jats:bold>\n                              <\/jats:p>\n          <\/jats:sec>","DOI":"10.1002\/hep.22487","type":"journal-article","created":{"date-parts":[[2008,7,9]],"date-time":"2008-07-09T13:06:29Z","timestamp":1215608789000},"page":"1412-1419","update-policy":"http:\/\/dx.doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":20,"title":["Interpretation of positive transcription-mediated amplification test results from polymerase chain reaction\u2013negative samples obtained after treatment of chronic hepatitis C"],"prefix":"10.1097","volume":"48","author":[{"given":"Chihiro","family":"Morishima","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy R.","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James E.","family":"Everhart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth C.","family":"Wright","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minjun C.","family":"Apodaca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David R.","family":"Gretch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitchell L.","family":"Shiffman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory T.","family":"Everson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen L.","family":"Lindsay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William M.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna S. F.","family":"Lok","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jules L.","family":"Dienstag","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc G.","family":"Ghany","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa M.","family":"Curto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-10-20241201","first-page":"1","article-title":"C: 2002.","volume":"19","year":"2002","journal-title":"NIH Consens State Sci Statements"},{"key":"R2-10-20241201","doi-asserted-by":"crossref","first-page":"875","DOI":"10.7326\/0003-4819-127-10-199711150-00003","article-title":"Longterm histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferonalpha therapy.","volume":"127","author":"Marcellin","year":"1997","journal-title":"Ann Intern Med"},{"key":"R3-10-20241201","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1002\/hep.510280430","article-title":"10year followup after interferonalpha therapy for chronic hepatitis C.","volume":"28","author":"Lau","year":"1998","journal-title":"HEPATOLOGY"},{"key":"R4-10-20241201","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/S0168-8278(99)80129-9","article-title":"Longterm followup of chronic hepatitis C patients with sustained virological response to alphainterferon.","volume":"30","author":"Reichard","year":"1999","journal-title":"J Hepatol"},{"key":"R5-10-20241201","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1053\/jhep.2002.31870","article-title":"Hepatic HCV RNA before and after treatment with interferon alone or combined with ribavirin.","volume":"35","author":"McHutchison","year":"2002","journal-title":"HEPATOLOGY"},{"key":"R6-10-20241201","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1002\/hep.20119","article-title":"Diagnosis, management, and treatment of hepatitis C.","volume":"39","author":"Strader","year":"2004","journal-title":"HEPATOLOGY"},{"key":"R7-10-20241201","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1002\/jcla.1042","article-title":"Performance characteristics of a transcriptionmediated nucleic acid amplification assay for qualitative detection of hepatitis C virus RNA.","volume":"15","author":"Ross","year":"2001","journal-title":"J Clin Lab Anal"},{"key":"R8-10-20241201","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1128\/JCM.41.1.310-317.2003","article-title":"Performance evaluation of the VERSANT HCV RNA qualitative assay by using transcriptionmediated amplification.","volume":"41","author":"Gorrin","year":"2003","journal-title":"J Clin Microbiol"},{"key":"R9-10-20241201","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1128\/JCM.41.2.651-656.2003","article-title":"Multicenter evaluation of the VERSANT HCV RNA qualitative assay for detection of hepatitis C virus RNA.","volume":"41","author":"Hendricks","year":"2003","journal-title":"J Clin Microbiol"},{"key":"R10-10-20241201","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1002\/hep.21265","article-title":"HCV RNA detection by TMA during the hepatitis C antiviral longterm treatment against cirrhosis (HALTC) trial.","volume":"44","author":"Morishima","year":"2006","journal-title":"HEPATOLOGY"},{"key":"R11-10-20241201","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1053\/jhep.2000.17709","article-title":"Detection of residual hepatitis C virus RNA by transcriptionmediated amplification in patients with complete virologic response according to polymerase chain reactionbased assays.","volume":"32","author":"Sarrazin","year":"2000","journal-title":"HEPATOLOGY"},{"key":"R12-10-20241201","doi-asserted-by":"crossref","first-page":"2850","DOI":"10.1128\/JCM.39.8.2850-2855.2001","article-title":"Assessment, by transcriptionmediated amplification, of virologic response in patients with chronic hepatitis C virus treated with peginterferon alpha2a.","volume":"39","author":"Sarrazin","year":"2001","journal-title":"J Clin Microbiol"},{"key":"R13-10-20241201","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1111\/j.1572-0241.2001.04669.x","article-title":"Transcriptionmediated amplification is more sensitive than conventional PCRbased assays for detecting residual serum HCV RNA at end of treatment.","volume":"96","author":"Comanor","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"R14-10-20241201","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jhep.2005.08.016","article-title":"Hepatitis C minimal residual viremia (MRV) detected by TMA at the end of PegIFN plus ribavirin therapy predicts posttreatment relapse.","volume":"44","author":"Gerotto","year":"2006","journal-title":"J Hepatol"},{"key":"R15-10-20241201","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.cct.2004.08.003","article-title":"Evolution of the HALTC Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders.","volume":"25","author":"Lee","year":"2004","journal-title":"Control Clin Trials"},{"key":"R16-10-20241201","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1128\/JCM.42.1.421-425.2004","article-title":"Strengths and limitations of commercial tests for hepatitis C virus RNA quantification.","volume":"42","author":"Morishima","year":"2004","journal-title":"J Clin Microbiol"},{"key":"R17-10-20241201","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1053\/j.gastro.2004.01.014","article-title":"Peginterferon alfa2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment.","volume":"126","author":"Shiffman","year":"2004","journal-title":"Gastroenterology"},{"key":"R18-10-20241201","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1007\/s10620-006-9735-7","article-title":"Prognostic significance of hepatitis C virus RNA detection by transcriptionmediated amplification with negative polymerase chain reaction during therapy with peginterferon alpha and ribavirin.","volume":"52","author":"Kadam","year":"2007","journal-title":"Dig Dis Sci"},{"key":"R19-10-20241201","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/hep.20518","article-title":"Persistence of hepatitis C virus in patients successfully treated for chronic hepatitis C.","volume":"41","author":"Radkowski","year":"2005","journal-title":"HEPATOLOGY"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep.22487","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01515467-200811000-00010","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T13:42:00Z","timestamp":1733060520000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01515467-200811000-00010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,11]]},"references-count":19,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2008]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.22487","relation":{},"ISSN":["0270-9139"],"issn-type":[{"type":"print","value":"0270-9139"}],"subject":[],"published":{"date-parts":[[2008,11]]}}}